epirubicin

You have access
Differences in Transport Characteristics and Cytotoxicity of Epirubicin and Doxorubicin in HepG2 and A549 Cells
KATSUHITO NAGAI, SHUHEI FUKUNO, MAHO SHIOTA, MAYUKO TAMURA, SAYAKA YABUMOTO and HIROKI KONISHI

Anticancer Research December 2021, 41 (12) 6105-6112; DOI: https://doi.org/10.21873/anticanres.15430
You have access
Angiographic Evaluation of Vascular Damage in Rat Liver After Administration of Epirubicin or Miriplatin
SHUICHI KISHIMOTO, HIROKI AOKI, RYOSUKE SUZUKI, MAI INOUE and SHOJI FUKUSHIMA

Anticancer Research January 2018, 38 (1) 247-251;
You have access
Epirubicin plus Paclitaxel Regimen as Second-line Treatment of Patients with Small-cell Lung Cancer
GIULIA PASELLO, PAOLO CARLI, FABIO CANOVA, LAURA BONANNO, VALENTINA POLO, GIULIA ZAGO, LOREDANA URSO, PIERFRANCO CONTE and ADOLFO FAVARETTO

Anticancer Research April 2015, 35 (4) 2183-2189;
You have access
Transarterial Chemoembolization with Miriplatin plus Epirubicin in Patients with Hepatocellular Carcinoma
AKINOBU TAWADA, TETSUHIRO CHIBA, YOSHIHIKO OOKA, NAOYA KANOGAWA, TOMOKO SAITO, TENYU MOTOYAMA, SADAHISA OGASAWARA, EIICHIRO SUZUKI, FUMIHIKO KANAI, MASAHARU YOSHIKAWA and OSAMU YOKOSUKA

Anticancer Research January 2015, 35 (1) 549-554;
You have access
Chemotherapy for Advanced Endometrial Cancer with Carboplatin and Epirubicin
SYED HAMMAD TIRMAZY, URMILA BARTHAKUR, AHMED EL-MODIR, SUHAIL ANWAR and INDRAJIT FERNANDO

Anticancer Research July 2014, 34 (7) 3793-3798;
You have access
Comparison Between DCF (Docetaxel, Cisplatin and 5-Fluorouracil) and Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as Palliative First-line Chemotherapy for Adenocarcinoma of the Upper Gastrointestinal Tract
AYSEGÜL ILHAN-MUTLU, MATTHIAS PREUSSER, SEBASTIAN F. SCHOPPMANN, REZA ASARI, AHMED BA-SSALAMAH, KATRIN SCHWAMEIS, URSULA PLUSCHNIG, PETER BIRNER, ANDREAS PÜSPÖK, JOHANNES ZACHERL and MICHAEL HEJNA

Anticancer Research August 2013, 33 (8) 3455-3459;
You have access
Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as Palliative First-line Chemotherapy for Gastroesophageal Adenocarcinoma
URSULA PLUSCHNIG, SEBASTIAN F. SCHOPPMANN, MATTHIAS PREUSSER, PHILIP DATLER, REZA ASARI, AHMED BA-SSALAMAH, KATRIN SCHWAMEIS, PETER BIRNER, JOHANNES ZACHERL and MICHAEL HEJNA

Anticancer Research March 2013, 33 (3) 1035-1039;
You have access
Initial Safety and Outcomes of Miriplatin plus Low-dose Epirubicin for Transarterial Chemoembolisation of Hepatocellular Carcinoma
JIN IWAZAWA, NAOKO HASHIMOTO, SHOICHI OHUE and TAKASHI MITANI

Anticancer Research November 2012, 32 (11) 5039-5044;

Main menu

User menu

Search

epirubicin